Engineered fibroblast growth factor 1 variants with increased proteolytic stability
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsSung Jin Park, Jennifer R. Cochran
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of screening for proteolytically stable growth factor variants, including, for example variants of human fibroblast growth factor 1 (FGF1) The present invention also provides for FGF1 variants comprising at least one amino acid substitution, an amino acid deletion, an amino acid addition and combinations thereof, wherein the resulting FGF1 variant exhibits increased proteolytic stability as compared to wild-type FGF1, as well as related uses.
Claims9
A variant of human fibroblast growth factor 1 (FGF1) of SEQ ID NO:1 comprising the amino acid substitution L131R, wherein the resulting FGF1 variant exhibits increased proteolytic stability as compared to wild-type FGF1 of SEQ ID NO:1, wherein said FGF1 variant is a fibroblast growth factor receptor (FGFR) antagonist.
Dependencies are inferred from the claim text.